SCHEMBL19348651

SCHEMBL19348651

C=CCCN(CCC=C)P(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LPAR2 Q9HBW0 1/20 0.38
LPAR3 Q9UBY5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006269 0.74 ALDH1A1 (0.41) LPAR2LPAR3
SCHEMBL1421700 0.69 LPAR2 (0.33) LPAR2LPAR3
SCHEMBL11777503 0.67 MAPT (0.33)
SCHEMBL585465 0.65
SCHEMBL8057037 0.65 FDPS (0.48) LPAR2LPAR3
Phosphoric Acid SCHEMBL27346285 0.65 LPAR3 (0.41) LPAR2LPAR3
SCHEMBL8069018 0.65 ALDH1A1 (0.45)
Phosphoric Acid SCHEMBL21753478 0.65 LPAR3 (0.41) LPAR2LPAR3
SCHEMBL28383776 0.65 LPAR3 (0.41) LPAR2LPAR3
SCHEMBL1395074 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222624-B1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO LTD (JP) 2019-11-06 EP disclosed
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CENTRAL GLASS CO., LTD. (JP) 2019-05-14 US disclosed
EP-3222624-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME Central Glass Co., Ltd. (JP) 2017-09-27 EP disclosed
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO., LTD. (JP) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CA2, CA6, CHRM1 LPAR2 2436/4885LPAR3 3163/4885
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CA2, CA6, CHRM1 LPAR2 2436/4885LPAR3 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.